ArticleMateria socio-medica2022
Diabetes Mellitus Type 2 and Cardiovascular Diseases-Risk Assessment.
Article in Materia socio-medica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The significance of ANGPTL3 and ANGPTL4 proteins in the development of dyslipidemia in Type 2 diabetes mellitus.Journal of family medicine and primary care · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Uncontrolled type 2 diabetes mellitus (T2DM) is widely recognized as a significant risk factor for the emergence of cardiovascular events. Early risk assessment, especially for coronary artery disease, is crucial to starting therapeutic strategies to lower cardiovascular risk. Objective: To assess cardiovascular risk in patients with type 2 diabetes mellitus. Methods: 64 patients were divided into groups according to age, gender, disease duration, glucoregulation, and applied treatment. The SCORE table was used to quantify cardiovascular risk. Results: Our research showed that cardiovascular risk in patients with diabetes mellitus increases with age (rho = 0.458; p = 0.0001; p <0.05) and is higher in men (rho = -0.417; p <0,0001). It has been found that patients with a longer duration of diabetes mellitus have a higher cardiovascular risk (rho = 0.266; p = 0.032). Patients with better glucoregulation had a slightly lower cardiovascular risk, but correlation was statistically insignificant. No statistically significant correlation was observed between applied therapy and cardiovascular risk. Conclusion: Good control and treatment of T2DM is of crucial importance for reducing cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.